Avanos Medical (AVNS) Q2 Revenue Up 2%
Avanos Medical (NYSE:AVNS), a medical technology firm specializing in digestive health and pain management devices, shared its financial results for Q2 2025 on August 5, 2025. The company delivered GAAP revenue and adjusted earnings surpassed Wall Street estimates, reporting $175.0 million in GAAP revenue (analyst estimate: $165.5 million) and $0.17 in adjusted EPS (non-GAAP) (analyst estimate: $0.15). Despite this outperformance, profitability fell sharply from the prior year due to margin compression tied to global tariffs, lower pricing in some product lines, and a significant $77.0 million goodwill impairment in the Pain Management Recovery segment. Management described "steady progress" against key transformation priorities and maintained its full-year 2025 guidance, though the quarter reflected persistent operating and regulatory pressures.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Avanos Medical develops and markets a range of devices for digestive health and pain management. The company’s product family includes MIC-KEY enteral feeding tubes, used for long-term nutritional support, and ON-Q pain pumps, devices that enable post-surgical non-opioid pain management. Additional portfolio highlights include the Corpak and NeoMed families, which serve neonatal and enteral feeding needs, and the radiofrequency ablation (RFA) systems sold under brand names like ESENTEC and TRIDENT, designed to manage chronic pain.
Source Fool.com
